Skip to Content
Søk Menu

Promising results for adjuvant pembrolizumab therapy in high-risk kidney cancer

Results from KEYNOTE-564 presented after the plenary session of ASCO 2021 show that adjuvant pembrolizumab therapy leads to a significant reduction in the risk of recurrence or death compared to placebo in patients with renal cell carcinoma.

Human Kidney Cross Section

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Real-World Data Show that Single-Agent Cabozantinib May Become the Second-Line Treatment of Metastatic Renal Cell Carcinoma

/ Sofie Pohl
Nyrekreft
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
BlærekreftESMO24NyrekreftProstatakreft Play the Video 4:25
Katriina Jalkanen

Belzutifan is Well-Tolerated and Might Be an Addition to a Standard of Care

/ Katriina Jalkanen
ESMO24Nyrekreft Play the Video 04:33
Umang Swami

Single-Agent Cabozantinib is Sufficient and Avoids Extra Toxicity in Metastatic Clear Cell Renal Cell Carcinoma Patients

/ Umang Swami
Nyrekreft Play the Video 06:01

Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors

/ Niels Fristrup
Nyrekreft

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

/ Sofie Pohl
Nyrekreft
Maria Teresa Bourlon

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

/ Maria Teresa Bourlon
Nyrekreft Play the Video 5:36
Wadih Issa

Comparing Downstaging in RCC-Patients with Tumor or Without Tumor Thrombus Receiving Neoadjuvant ICI Regimen

/ Wadih Issa
ASCOGU24Nyrekreft Play the Video 1:47
Marc Machaalani

Host Immune Signatures as Predictors for Immunotherapy Regimens in Patients with Metastatic Renal Cell Carcinoma

/ Marc Machaalani
Nyrekreft Play the Video 2:11
Back to top